Polatuzumab (Anti-CD79b)

製品コードA2550 別名: CD79B,B29 純度：99%

Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫なし(納期7~10日)
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 3.74mg/ml 内毒素：＜1EU/mg

CD markers阻害剤の選択性比較

生物活性

製品説明	Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD.

製品説明

CAS No.	2279068-37-8
Molecular Weight	145.5 kDa
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07638722	NOT_YET_RECRUITING	Drug: Polatuzumab Vedotin\|Drug: Zanubrutinib	Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Nodal Marginal Zone Lymphoma; Refractory Splenic Marginal Zone Lymphoma	SWOG Cancer Research Network	2026-10-03	PHASE2
NCT05283720	ACTIVE_NOT_RECRUITING	Drug: Epcoritamab\|Drug: Lenalidomide\|Drug: Ibrutinib\|Drug: R	Non-Hodgkin Lymphoma	Genmab	2022-06-14	PHASE2
NCT07654426	RECRUITING	Drug: Dexrazoxane\|Drug: Dexrazoxane placebo\|Drug: Doxorubici	Diffuse Large B-cell Lymphoma (DLBCL); Cardiotoxicity; Lymphoma	Beth Israel Deaconess Medical Center	2026-08-31	PHASE2
NCT07714421	NOT_YET_RECRUITING	Drug: Cyclophosphamide\|Drug: Doxorubicin\|Drug: Polatuzumab V	Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; Primary Mediastinal Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma	Jonsson Comprehensive Cancer Center	2026-12-08	PHASE1
NCT07184788	NOT_YET_RECRUITING	Drug: Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxal	Aggressive B-Cell Lymphoma	Navy General Hospital, Beijing	2025-10-01	PHASE2
NCT07702851	NOT_YET_RECRUITING	Drug: Polatuzumab vedotin, Glofitamab	Diffuse Large B-cell Lymphoma	Yonsei University	2026-09-01	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-13)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須